click the colored bars to visit the associated page.
Paclitaxel encapsulated in NanoPro™ nanoparticles for the treatment of Paclitaxel/Abraxane®-resistant metastatic breast cancer
Tetra-block nanoparticles encapsulating paclitaxel (Nanoxane™) generated using our proprietary NanoPro™ technology are stealth, long circulating and have a superior pharmacokinetic profile compared to Abraxane®
or Genexol-PM (Cynviloq™ in the USA acquired by Nantworks, Inc.
for up to $1.3 Billion). The disintegration of nanoparticles and release of paclitaxel from Nanoxane™ is much slower compared to these Abraxane®
-resistant metastatic breast cancer is an orphan, unmet need. Eventually most patients become resistant to Paclitaxel treated-metastatic breast cancers.
Irinotecan encapsulated in NanoPro™ nanoparticles for the treatment of Irinotecan-resistant metastatic colon cancer and metastatic triple negative breast cancer.
A diagnosis of metastatic irinotecan-resistant colon cancer and advanced triple negative breast cancer are devastating and there are no therapies approved to treat these specific patient populations. In fact, the incidence of breast cancer brain metastases is between 10-30 percent.
Top I is a validated target and its inhibition is as an important DNA-damaging mechanism for the treatment of colon and other cancers. However, the existing class of Top I inhibitors have had limited utility for patients because of their small therapeutic window. Following treatment these existing Top I agents reach peak concentrations and diffuse quickly throughout the body damaging healthy tissues and cause severe toxicities such as Diarrhea and Neuripenia. These characterisitcs have limited their ability to be explored for the treatment of advanced metastatic colon and other cancers.
Nanotecan™ (irinotecan-encapsulated in NanoPro™) is a long-acting Top I-inhibitor. Nanotecan™ is a novel formulation of irinotecan in a tetra block stealth polymeric biodegradable nanoparticles designed to enhance the anti-tumor activity of Top I-inhibition while minimizing its toxicities.
Tetra-block nanoparticles encapsulating irinotecan (Nanotecan™) generated using our proprietary NanoPro™ technology are stealth, long circulating nanoparticles and will have a superior pharmacokinetic profile compared to irinotecan and recently approved agent ‘Onivyde’. The disintegration of nanoparticles and release of irinotecan from Nanotecan™ is much slower compared to irinotecan and Onivyde.
Irinotecan-resistant metastatic colon cancer and metastatic triple negative breast cancer are orphan indications with significant unmet medical needs. Eventually most patients become resistant to Irinotecan treated-metastatic colon cancers.